Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

(2019) Nolwenn Lucas et al.   LEUKEMIA

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm

(2019) Naveen Pemmaraju et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm

(2019) Phyu P. Aung et al.   Cancers

Dual Expression of TCF4 and CD123 is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm

(2019) Narittee Sukswai et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance

(2019) Katsuhiro Togami et al.   JOURNAL OF CLINICAL INVESTIGATION

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34 + CD123 + cells from acute myeloid leukemia / myelodysplastic syndrome patients and healthy donors

(2018) Rajeswaran Mani et al.   HAEMATOLOGICA

First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

(2018) Weili Sun et al.   Journal of Hematology & Oncology

Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response

(2018) Kana Sakamoto et al.   LEUKEMIA

A dual role for the N-terminal domain of the IL-3 receptor in cell signalling

(2018) Sophie E. Broughton et al.   Nature Communications

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34 + CD123 + cells from acute myeloid leukemia / myelodysplastic syndrome patients and healthy donors

(2018) Rajeswaran Mani et al.   HAEMATOLOGICA

Survival outcomes of CD34+CD38−LSCs and their expression of CD123 in adult AML patients

(2018) Asmaa M. Zahran et al.   Oncotarget

Moxetumomab Pasudotox: First Global Approval

(2018) Sohita Dhillon   DRUGS

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

(2018) Maria Rosaria Sapienza et al.   HAEMATOLOGICA

Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm

(2018) Mounzer E. Agha et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blastic Plasmacytoid Dendritic Cell Neoplasm

(2018) Joseph D. Khoury   Current Hematologic Malignancy Reports

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community

(2018) Naveen Pemmaraju et al.   Current Hematologic Malignancy Reports

A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells

(2017) A Ray et al.   LEUKEMIA

Novel treatment of blastic plasmacytoid dendritic cell neoplasm

(2017) Solomiya Grushchak et al.   MEDICINE

Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

(2017) Naveen Pemmaraju   Current Hematologic Malignancy Reports

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy

(2016) Uday Deotare et al.   AMERICAN JOURNAL OF HEMATOLOGY

Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms

(2016) A. Emadali et al.   BLOOD

A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm

(2016) Michele Ceribelli et al.   CANCER CELL

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

(2016) Joan Montero et al.   Cancer Discovery

Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy

(2016) Lourdes Martín-Martín et al.   Oncotarget

Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm

(2015) T. Aoki et al.   BLOOD

Allogeneic Hematopoietic Stem Cell Transplantions in Blastic Plasmacytoid Dendritic Cell Neoplasm in first complete remission: an effective therapy for a rare disease

(2015) Uday Deotare et al.   LEUKEMIA & LYMPHOMA

Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile

(2015) Lourdes Martín-Martín et al.   Oncotarget

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

(2014) A. E. Frankel et al.   BLOOD

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

(2014) Olga Frolova et al.   BRITISH JOURNAL OF HAEMATOLOGY

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

(2014) F. Angelot-Delettre et al.   HAEMATOLOGICA

Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition

(2014) M R Sapienza et al.   LEUKEMIA

Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation

(2013) Mohamed A. Kharfan-Dabaja et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients

(2013) F. Julia et al.   BRITISH JOURNAL OF DERMATOLOGY

L-asparaginase with methotrexate and dexamethasone is an effective treatment combination in blastic plasmacytoid dendritic cell neoplasm

(2013) Bérengère Gruson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies

(2013) Madeleine Duvic et al.   Clinical Lymphoma Myeloma & Leukemia

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study

(2013) L. Pagano et al.   HAEMATOLOGICA

Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm

(2013) J Menezes et al.   LEUKEMIA

Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8

(2013) Xiaobo Hu et al.   LEUKEMIA RESEARCH

Sequential combination of high dose methotrexate andl-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm

(2012) Lila Gilis et al.   LEUKEMIA & LYMPHOMA

TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm

(2011) Fabrice Jardin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?

(2009) S. Dalle et al.   BRITISH JOURNAL OF DERMATOLOGY

Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: Results from the Hellenic Dendritic Cell Leukemia Study Group

(2009) Nikolaos J. Tsagarakis et al.   LEUKEMIA RESEARCH

Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor

(2008) Roberta Riccioni et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia

(2008) Arthur Frankel et al.   LEUKEMIA & LYMPHOMA